Laboratorios Farmaceuticos Rovi, S.A.
LABFFOTCHealthcare● Active
$90.61
+$0.00(+0.00%)
Market Cap$4.6B
P/E Ratio—
52W High$90.61
52W Low$90.61
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LABFF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.74B | $0.76B | $0.83B | $0.82B | $0.65B |
| Cost of Revenue | $0.29B | $0.30B | $0.35B | $0.31B | $0.27B |
| Gross Profit | $0.45B | $0.47B | $0.48B | $0.51B | $0.38B |
| Gross Margin %(computed) | 60.75% | 61.24% | 58.27% | 62.67% | 58.56% |
| Operating Expenses | |||||
| R&D Expenses | $0.04B | $0.03B | $0.03B | $0.02B | $0.03B |
| G&A Expenses | $0.00B | $0.14B | $0.13B | $0.11B | $0.09B |
| Total Operating Expenses | $0.28B | $0.29B | $0.26B | $0.26B | $0.20B |
| Operating Income | $0.17B | $0.18B | $0.22B | $0.26B | $0.18B |
| Operating Margin %(computed) | 23.29% | 23.51% | 26.55% | 31.29% | 27.96% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.18B | $0.18B | $0.22B | $0.26B | $0.18B |
| Income Tax Expense | $0.04B | $0.04B | $0.05B | $0.06B | $0.03B |
| Net Income | $0.14B | $0.14B | $0.17B | $0.20B | $0.15B |
| Net Margin %(computed) | 18.89% | 17.92% | 20.53% | 24.42% | 23.60% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.75 | $2.67 | $3.20 | $3.73 | $2.76 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.06B |
| EBITDA | $0.20B | $0.20B | $0.24B | $0.27B | $0.20B |
| EBITDA Margin %(computed) | 27.37% | 26.14% | 28.69% | 33.18% | 30.30% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · EUR · B
Explore more Laboratorios Farmaceuticos Rovi, S.A. data
About Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Income Statement
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, LABFF reported revenue of $0.74B, gross profit of $0.45B (gross margin 60.75%), and net income of $0.14B — a net profit margin of 18.89%.
Frequently asked questions
LABFF · 4 questionsLaboratorios Farmaceuticos Rovi, S.A. (LABFF) reported revenue of $0.74B for 2025, down 2.7% year-over-year.
LABFF revenueLABFF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09